Search results
Showing 46 to 60 of 71 results for psoriasis
Biographies and registered interests for members of the Technology Appraisal Committee A
Tofacitinib for treating juvenile idiopathic arthritis (TA735)
Evidence-based recommendations on tofacitinib for treating juvenile idiopathic arthritis.
Find out more about NICE technology appraisals advisory committee D members
Discontinued [GID-TAG412]
Secukinumab for treating non-radiographic axial spondyloarthritis (TA719)
Evidence-based recommendations on secukinumab (Cosentyx) for treating non-radiographic axial spondyloarthritis in adults.
Summary of the evidence on remsima (infliximab biosimilar) for subcutaneous injection for managing Crohn’s disease and ulcerative colitis
treatment of malignant pleural mesothelioma (2) 23 November 2007 TA103 Psoriasis - efalizumab and etanercept 27 January 2006 TA104...
guidance Certolizumab pegol for treating moderate to severe plaque psoriasis Number TA574 Date issued April 2019 Other details
from guidance Tildrakizumab for treating moderate to severe plaque psoriasis Number TA575 Date issued April 2019 Other details
Summary of the evidence on infliximab for treating refractory extrapulmonary sarcoidosis to inform local NHS planning and decision-making
This quality standard covers interventions to improve the uptake of HIV testing among people who may have undiagnosed HIV. It focuses on increasing testing to reduce undiagnosed infection in people at increased risk of exposure. It describes high-quality care in priority areas for improvement.
View quality statements for QS157Show all sections
Sections for QS157
- Quality statements
- Quality statement 1: Hospitals in areas of high and extremely high HIV prevalence
- Quality statement 2: General practice in areas of high and extremely high HIV prevalence
- Quality statement 3: HIV indicator conditions
- Quality statement 4: Regular HIV testing
- Quality statement 5: People who may have been exposed to HIV
- Update information
- About this quality standard